SWOG clinical trial number
S2433
Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS Wild Type Pancreatic Adenocarcinoma
Open
Phase
Accrual
0%
Abbreviated Title
Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS Wild Type Pancreatic Adenocarcinoma
Activated
12/26/2025
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS
Research committees
Gastrointestinal Cancer
Treatment
Panitumumab
Other Clinical Trials
SWOG Clinical Trial Number
S2433
Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS Wild Type Pancreatic Adenocarcinoma
Research Committee(s)
Gastrointestinal Cancer
Activated
12/26/2025
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2303
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Accrual
33%
Open
Phase
SWOG Clinical Trial Number
CTSU/A022101
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase